Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

EC approves Biogen's Spinraza for SMA

Alicia Parker
June 2, 2017 7:18 PM UTC

The European Commission approved Spinraza nusinersen (IONIS-SMNRx) from Biogen Inc. (NASDAQ:BIIB) to treat spinal muscular atrophy (SMA). Biogen has rights to Spinraza from Ionis Pharmaceuticals Inc. (NASDAQ:IONS). The approval triggered a $50 million milestone payment to Ionis, which is also eligible for tiered royalties (see BioCentury, Aug. 8, 2016)...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Biogen Inc.

Ionis Pharmaceuticals Inc.